Coronary Artery Disease
Conditions
Brief summary
The purpose of this study is to evaluate the safety, efficacy and deliverability of the CRE8 sirolimus-eluting stent and the RESOLUTE zotarolimus-eluting stent in the treatment of patients with de novo coronary artery lesions.
Detailed description
This study consists of a randomized controlled cohort and a long stent observational cohort. The randomized controlled trial is a prospective, multi-center, non-inferior, randomized controlled trial. The control device (RESOLUTE zotarolimus-eluting stent) used in this trial was provided by Medtronic. RESOLUTE zotarolimus-eluting stent has been already approved by China Food and Drug Administration (CFDA) in 2009 and become commercially available in Chinese market. 400 patients enrolled in this trial will be randomly assigned to CRE8 group (n=200) and RESOLUTE group (n=200) in a 1:1 ratio. The long stent observational trial plans to enroll 30 consecutive patients. Patients in the observational cohort will receive the long CRE8 stent with length 38mm.All 430 patients will be required to receive clinical follow-up at 1 month, 6 months, 9 months, 12 months and annually up to 5 years after the procedure, and angiographic follow-up at 9 months after the procedure. The primary endpoint is in-stent LLL at 9 months after the procedure, and the secondary endpoints are device success rate, device-oriented cardiovascular composite endpoint, patient-oriented cardiovascular composite endpoint and stent thrombosis.
Interventions
The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
DEVICERESOLUTE zotarolimus-eluting stent
The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
Sponsors
CID S.p.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Inclusion criteria for randomized cohort: * Age ≥18 years and ≤ 75 years, male or female without pregnancy; * Patients with clinical evidence of asymptomatic heart disease, stable or unstable angina, or old myocardial infarction; * De novo lesions of native coronary arteries (lesions number ≤ 2); * Target vessel diameter between 2.25 and 4.0 mm and target lesion length ≤ 27mm by visual estimation; * Target lesion diameter stenosis ≥ 70% by visual estimation; * Each target lesion is permitted to implant only one stent at most, except bailout stent; * Patients is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG); * Patients with left ventricular ejection fraction ≥40%; * Patients who can understand the nature of the study, agree to participate and accept angiographic and clinical follow-up, and have provided written informed consent. Inclusion criteria for the long stent observational cohort: * Age ≥18 years and ≤ 75 years, male or female without pregnancy; * Patients with clinical evidence of asymptomatic heart disease, stable or unstable angina, or old myocardial infarction; * De novo lesions of native coronary arteries (lesions number ≤ 2); * Target lesion diameter stenosis ≥ 70% by visual estimation; * At least one target lesion with reference vessel diameter between 2.5mm and 4.0mm and requires 38mm stent exists; * Patients is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG); * Patients with left ventricular ejection fraction ≥40%; * Patients who can understand the nature of the study, agree to participate and accept angiographic and clinical follow-up, and have provided written informed consent.
Exclusion criteria
* Patients with acute myocardial infarction (AMI) within one week; * Chronic total occlusion lesion (TIMI flow 0 before procedure), Left main disease and/or triple-vessel lesion that might require treatment, bifurcation lesions with a side branch diameter \>2.5mm or graft lesions; * Heavily calcified or tortuous lesions which cannot be successfully pre-dilated, and lesions which are not suitable for stent delivery and deployment; * In-stent restenosis; * Thrombotic lesion; * Patients who had received any other stent in the past one year; * Patients with acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl); * Patients with cardiogenic shock, acute infection, known bleeding or coagulation disorder, or with a history of active gastrointestinal bleeding, ulcer, cerebral hemorrhage or subarachnoid hemorrhage and stroke within 6 months; * Patients who allergic to aspirin, clopidogrel, ticagrelor, ticlopidine, heparin, contrast agent, sirolimus, zotarolimus, polymer, Co-Cr alloy, or with contraindication to aspirin or clopidogrel or ticagrelor; * Patients with life expectancy less than 1year; * Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint; * Patient is in the opinion of the investigator, unable to comply with the requirements of the study protocol; * Patients who had underwent heart transplant surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In-stent late lumen loss (LLL) | 9months after the procedure |
Secondary
| Measure | Time frame |
|---|---|
| In-segment late lumen loss (LLL) | 9months after the procedure |
| Target lesion failure (TLF) rate | 1month, 6months, 9months, 12months and annually up to 5 years follow-up |
| Number of participants with stent thrombosis per ARC definition | 1month, 6months, 9months, 12months and annually up to 5 years follow-up |
| In-stent, proximal stent edge, distal stent edge and In-segment binary restenosis rate | 9months after the procedure |
| device and lesion success rates | immediately after the procedure |
| clinical success rate | 7 days after the procedure |
| The patient-oriented composite endpoint includes all-cause death, all MIs, or any revascularizations | 1month, 6months, 9months, 12months and annually up to 5 years follow-up |
Countries
China
Contacts
Primary ContactShubin Qiao, MD
Outcome results
None listed